CN104363903A - 用作蛋白聚集抑制剂的苯基脲和苯基氨基甲酸盐/酯衍生物 - Google Patents

用作蛋白聚集抑制剂的苯基脲和苯基氨基甲酸盐/酯衍生物 Download PDF

Info

Publication number
CN104363903A
CN104363903A CN201380017441.6A CN201380017441A CN104363903A CN 104363903 A CN104363903 A CN 104363903A CN 201380017441 A CN201380017441 A CN 201380017441A CN 104363903 A CN104363903 A CN 104363903A
Authority
CN
China
Prior art keywords
ethyl
indol
compound
methyl
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380017441.6A
Other languages
English (en)
Chinese (zh)
Inventor
W·赖斯德罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuropore Therapies Inc
Original Assignee
Neuropore Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuropore Therapies Inc filed Critical Neuropore Therapies Inc
Publication of CN104363903A publication Critical patent/CN104363903A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380017441.6A 2012-03-28 2013-03-15 用作蛋白聚集抑制剂的苯基脲和苯基氨基甲酸盐/酯衍生物 Pending CN104363903A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616771P 2012-03-28 2012-03-28
US61/616,771 2012-03-28
PCT/US2013/032552 WO2013148365A1 (en) 2012-03-28 2013-03-15 Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation

Publications (1)

Publication Number Publication Date
CN104363903A true CN104363903A (zh) 2015-02-18

Family

ID=49261100

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380017441.6A Pending CN104363903A (zh) 2012-03-28 2013-03-15 用作蛋白聚集抑制剂的苯基脲和苯基氨基甲酸盐/酯衍生物

Country Status (15)

Country Link
US (1) US9527852B2 (cg-RX-API-DMAC7.html)
EP (1) EP2830608B8 (cg-RX-API-DMAC7.html)
JP (1) JP6159388B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150002713A (cg-RX-API-DMAC7.html)
CN (1) CN104363903A (cg-RX-API-DMAC7.html)
AU (1) AU2013240219A1 (cg-RX-API-DMAC7.html)
CA (1) CA2867175A1 (cg-RX-API-DMAC7.html)
ES (1) ES2768602T3 (cg-RX-API-DMAC7.html)
HK (1) HK1202452A1 (cg-RX-API-DMAC7.html)
IL (1) IL234825A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN08633A (cg-RX-API-DMAC7.html)
MX (1) MX2014011615A (cg-RX-API-DMAC7.html)
NZ (1) NZ631388A (cg-RX-API-DMAC7.html)
RU (1) RU2014143242A (cg-RX-API-DMAC7.html)
WO (1) WO2013148365A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2016009347A0 (en) 2014-01-29 2016-07-31 Neuropore Therapies Inc Heteroarly amides as inhibitors of protein aggregation
WO2016040780A1 (en) * 2014-09-11 2016-03-17 Neuropore Therapies, Inc. Aminomethyl- and methyloxy-linked tricyclic compounds as inhibitors of protein aggregation
EP3328379B1 (en) 2015-07-29 2021-07-28 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
EA201991755A1 (ru) 2017-01-26 2020-01-22 Юсб Байофарма Спрл Бициклические бисгетероарильные производные в качестве модуляторов агрегации белков
CN110198938B (zh) 2017-01-26 2023-03-14 Ucb生物制药私人有限公司 作为蛋白质聚集调节剂的双-杂芳基衍生物
KR20190112031A (ko) 2017-01-26 2019-10-02 유씨비 바이오파마 에스피알엘 단백질 응집의 조절제로서의 알콕시 비스-헤테로아릴 유도체

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125354A1 (en) * 1999-11-16 2003-07-03 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds use as anti-inflammatory agents
EP1402888A1 (en) * 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US20040097499A1 (en) * 1998-07-31 2004-05-20 Arnold Macklin Brian Amide, carbamate, and urea derivatives
WO2011084642A1 (en) * 2009-12-16 2011-07-14 Neuropore Therapies, Inc. Compound suitable for the treatment of synucleopathies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096758A (en) 1996-01-26 2000-08-01 Byk Gulden Lomberg Chemische Fabrik Gmbh 3-methylimidazopyridines
HU228960B1 (hu) * 2000-10-30 2013-07-29 Kudos Pharm Ltd Ftalazinon-származékok
EP1606247A1 (en) * 2003-03-14 2005-12-21 H. Lundbeck A/S Substituted aniline derivatives
WO2004082677A1 (en) * 2003-03-21 2004-09-30 H. Lundbeck A/S Substituted p-diaminobenzene derivatives
EP1684762A4 (en) * 2003-11-13 2009-06-17 Ambit Biosciences Corp UREA DERIVATIVES AS MODULATORS OF KINASE
UA95244C2 (ru) * 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
US8097626B2 (en) 2006-04-21 2012-01-17 Glaxosmithkline Llc IL-8 receptor antagonists
WO2008044688A1 (en) * 2006-10-11 2008-04-17 Daiichi Sankyo Company, Limited Urea derivative
WO2010036316A1 (en) 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097499A1 (en) * 1998-07-31 2004-05-20 Arnold Macklin Brian Amide, carbamate, and urea derivatives
US20030125354A1 (en) * 1999-11-16 2003-07-03 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds use as anti-inflammatory agents
EP1402888A1 (en) * 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
WO2011084642A1 (en) * 2009-12-16 2011-07-14 Neuropore Therapies, Inc. Compound suitable for the treatment of synucleopathies

Also Published As

Publication number Publication date
EP2830608A1 (en) 2015-02-04
NZ631388A (en) 2016-01-29
US20150166543A1 (en) 2015-06-18
EP2830608B8 (en) 2020-01-15
AU2013240219A1 (en) 2014-10-09
ES2768602T3 (es) 2020-06-23
KR20150002713A (ko) 2015-01-07
JP2015515465A (ja) 2015-05-28
EP2830608B1 (en) 2019-12-11
EP2830608A4 (en) 2015-08-19
IL234825A0 (en) 2014-12-31
HK1202452A1 (en) 2015-10-02
RU2014143242A (ru) 2016-05-20
MX2014011615A (es) 2015-01-19
WO2013148365A1 (en) 2013-10-03
US9527852B2 (en) 2016-12-27
JP6159388B2 (ja) 2017-07-05
CA2867175A1 (en) 2013-10-03
IN2014DN08633A (cg-RX-API-DMAC7.html) 2015-05-22

Similar Documents

Publication Publication Date Title
CN110198938B (zh) 作为蛋白质聚集调节剂的双-杂芳基衍生物
EP3215156B1 (en) Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase
US11053207B2 (en) Indoleamine-2,3-dioxygenase inhibitor and preparation method therefor
US10975066B2 (en) Bis-heteroaryl derivatives as modulators of protein aggregation
CN104363903A (zh) 用作蛋白聚集抑制剂的苯基脲和苯基氨基甲酸盐/酯衍生物
KR20150031481A (ko) 단백질 응집 저해제로서의 디- 및 트리-헤테로아릴 유도체
US9062061B2 (en) Compound having PARP inhibitory activity
KR101463190B1 (ko) ５­ｈｔ６ 수용체 리간드인 술폰 화합물
KR102639231B1 (ko) 치환된 페닐 설폰일 페닐 트리아졸 싸이온 및 이의 용도
CN110191885A (zh) 作为蛋白质聚集调节剂的烷氧基双-杂芳基衍生物
CA3048947C (en) Bis-heteroaryl derivatives as modulators of protein aggregation
JP2018016572A (ja) Ｎ−ピリダジン−３−イルスルホンアミド誘導体
HK40012937A (en) Bis-heteroaryl derivatives as modulators of protein aggregation
BR112017009134B1 (pt) Composto, composição farmacêutica, kit farmacêutico para tratamento de um câncer, e, métodos para tratamento de uma doença e/ou uma condição e/ou um distúrbio e para síntese de um composto
EA043772B1 (ru) Производные буметанида для лечения гипергидроза

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150218

WD01 Invention patent application deemed withdrawn after publication